Smart technology for clinical decisions

Proventys and the National Comprehensive Cancer Network^® (NCCN^®) have formed a strategic collaboration to develop an innovative, web-based system to support the clinical decision-making needs of oncology practices. Proventys CDS Oncology allows clinicians to access and navigate the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) efficiently within the clinical workflow, and create personalized care plans based on patient-specific data. CDS Oncology will offer optional order-entry functionality and serves as the point-of-care platform for the AlignQI pathways program.

The quality approach for pathways

AlignQI is a unique pathways program centered on practices’ use of Proventys CDS Oncology to support the delivery of high-quality, evidence-based care. AlignQI maintains the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) as its foundation and embeds clinician-derived pathways and payer-specific coverage policies to help inform key decisions, reduce administrative burdens, and facilitate ongoing data collection and reporting.

Predictive medicine, personalized care

Proventys is developing a suite of software-based predictive and prognostic tests, delivered through Proventys PDx Oncology, to help clinicians assess certain patient risks and individualize treatment decisions. The first version of PDx Oncology includes the FN PDx™, a predictive test to assess a patient’s risk of febrile neutropenia, a serious complication of chemotherapy.

Under review by the FDA (de novo); not available for sale in the United States.